tissue-engineering
(5)
Ventrix Put Pig-Heart Scaffolding in a Catheter. Now Comes the Hard Part.
A tiny San Diego biotech turned the heart's natural scaffolding into an injectable material, survived the first human test, and then redesigned the delivery. The idea is elegant. Proving it works at scale is the expensive part.
Fount Bio, Inc.
Fount Bio is a Somerville, Massachusetts life-science company that builds long-lasting hyaluronic acid (HA) matrices directly inside living tissue. Its proprietary Flī-HA platform uses Nobel-Prize-winning bioorthogonal (click) chemistry to deliver HA building blocks that self-assemble in situ into a biostable, high-molecular-weight matrix - overcoming the delivery and degradation barriers that have long forced HA to be injected as pre-formed filler. The lead product, Flī-Derm, is a needle-free liquid for aesthetic dermatology that reduced fine lines and wrinkles in a blinded clinical study and won IMCAS 2024's Innovation of the Year. The tunable platform extends toward ophthalmology, joints, mucosal tissue and women's health.
Curi Bio
Curi Bio is a Seattle biotechnology company building human-relevant preclinical platforms for drug discovery. By combining human iPSC-derived cells, 3D engineered tissues, lab instruments, and AI/ML data analysis, it gives biopharma teams functional human data earlier in development - aiming to bridge the gap between animal/2D-cell models and the clinic across cardiac, skeletal muscle, metabolic, and neuromuscular diseases.
Morphocell Technologies
Morphocell Technologies is a Montreal-area regenerative medicine company building allogeneic, stem cell-derived engineered tissues to treat severe organ deficiencies, starting with the liver. Its lead program, ReLiver, is a transiently implanted engineered liver tissue made from induced pluripotent stem cells (iPSCs) intended to treat acute and acute-on-chronic liver failure without immunosuppression. Spun out of CHU Sainte-Justine in 2018, the company has raised US$50 million in Series A funding and runs vertically integrated operations spanning discovery, cell manufacturing and preclinical development.
Fork & Good, Inc.
Fork & Good is a Jersey City-based cellular agriculture company growing real meat from animal cells instead of whole animals. Founded by urban-farming entrepreneur Niya Gupta and cultivated-meat pioneer Gabor Forgacs, the company built a pilot factory that produces cultivated pork using a patented bioprocess centered on muscle cells and high-density bioreactors. Its goal is to reach price parity with commodity meat - targeting roughly $2 per pound - while using a fraction of the land and water of conventional farming. In 2025 it acquired California's Orbillion Bio to combine cultivated pork and beef under one global platform spanning North America, Europe, Asia and the Middle East.